SCHEMBL20129253

SCHEMBL20129253

Brc1ccc(OC2CC3(CNC3)C2)nc1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.40
HSD11B1 P28845 2/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
HCRTR1 O43613 8/20 0.32
HCRTR2 O43614 8/20 0.32
HSD11B2 P80365 1/20 0.31
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31
HTR2B P41595 1/20 0.31
HTR6 P50406 1/20 0.31
ATR Q13535 1/20 0.31
TDO2 P48775 1/20 0.30
P2RX3 P56373 1/20 0.30
P2RX2 Q9UBL9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129265 0.83 DGAT1 (0.35) DGAT1
SCHEMBL31239610 0.82 TDO2 (0.40) DGAT1HCRTR1HCRTR2ATRTDO2
SCHEMBL31401100 0.82 KCNH2 (0.42) DGAT1HSD11B1HCRTR1HCRTR2HSD11B2
SCHEMBL31239617 0.82 ATR (0.38) DGAT1DDB1CRBNHCRTR1HCRTR2
SCHEMBL22711853 0.81 DGAT1 (0.43) DGAT1HSD11B1HCRTR1HCRTR2HSD11B2
SCHEMBL30884069 0.81 DGAT1 (0.43) DGAT1HSD11B1HCRTR1HCRTR2HSD11B2
SCHEMBL30314525 0.79 SLC6A4 (0.43) DGAT1HTR2CSLC6A4HTR2BHTR6
SCHEMBL10078051 0.79 SLC6A4 (0.43) DGAT1HTR2CSLC6A4HTR2BHTR6
Hydrochloric Acid SCHEMBL31347800 0.78 SLC6A4 (0.42) DGAT1HTR2CSLC6A4HTR2BHTR6
Hydrochloric Acid SCHEMBL517567 0.78 SLC6A4 (0.42) DGAT1HTR2CSLC6A4HTR2BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN DGAT1 4519/4885HSD11B1 4020/4885DDB1 433/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 DGAT1 4651/4885HSD11B1 4133/4885DDB1 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.